tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

Ascletis Reports Positive Long-Term Phase III Safety Data for First-in-Class Oral Acne Drug Denifanstat
Company AnnouncementsAscletis Reports Positive Long-Term Phase III Safety Data for First-in-Class Oral Acne Drug Denifanstat
2d ago
1672
Ascletis Starts U.S. Phase II Diabetes Trial of Oral GLP-1 Drug ASC30 After Strong Obesity Data
PremiumCompany Announcements
Ascletis Starts U.S. Phase II Diabetes Trial of Oral GLP-1 Drug ASC30 After Strong Obesity Data
6d ago
1672
Ascletis Advances Next-Generation Once-Monthly Triple Agonist ASC37 for Obesity Into Clinical Pathway
PremiumCompany Announcements
Ascletis Advances Next-Generation Once-Monthly Triple Agonist ASC37 for Obesity Into Clinical Pathway
11d ago
1672
Ascletis Wins FDA Green Light for Phase II U.S. Diabetes Trial of Oral GLP-1 Drug ASC30
PremiumCompany Announcements
Ascletis Wins FDA Green Light for Phase II U.S. Diabetes Trial of Oral GLP-1 Drug ASC30
27d ago
1672
Ascletis Pharma Upsizes Share Repurchase to HK$500 Million Amid Drug Development Success
PremiumCompany Announcements
Ascletis Pharma Upsizes Share Repurchase to HK$500 Million Amid Drug Development Success
2M ago
1672
Ascletis Pharma Reports Positive Phase I Results for ASC50
PremiumCompany AnnouncementsAscletis Pharma Reports Positive Phase I Results for ASC50
2M ago
1672
Ascletis Pharma’s Acne Treatment Drug Application Accepted by China NMPA
Premium
Company Announcements
Ascletis Pharma’s Acne Treatment Drug Application Accepted by China NMPA
2M ago
1672
Ascletis Pharma’s ASC30 Shows Promising Results in Obesity Treatment Study
Premium
Company Announcements
Ascletis Pharma’s ASC30 Shows Promising Results in Obesity Treatment Study
2M ago
1672
Ascletis Pharma Advances ASC37 for Obesity Treatment
PremiumCompany Announcements
Ascletis Pharma Advances ASC37 for Obesity Treatment
2M ago
1672
Ascletis Pharma Advances Obesity Treatment with New Co-Formulation
PremiumCompany Announcements
Ascletis Pharma Advances Obesity Treatment with New Co-Formulation
3M ago
1672
Ascletis Pharma Unveils Promising Obesity Treatment Results at ObesityWeek 2025
PremiumCompany Announcements
Ascletis Pharma Unveils Promising Obesity Treatment Results at ObesityWeek 2025
3M ago
1672
Ascletis Pharma Advances ASC36 for Obesity Treatment
PremiumCompany Announcements
Ascletis Pharma Advances ASC36 for Obesity Treatment
3M ago
1672
Ascletis Pharma to Showcase Obesity Treatment Advances at ObesityWeek 2025
PremiumCompany AnnouncementsAscletis Pharma to Showcase Obesity Treatment Advances at ObesityWeek 2025
3M ago
1672
Ascletis Completes Enrollment for Phase IIa Study of ASC30 for Obesity
Premium
Company Announcements
Ascletis Completes Enrollment for Phase IIa Study of ASC30 for Obesity
3M ago
1672
Ascletis Pharma Advances Acne Treatment with Pre-NDA Completion
Premium
Company Announcements
Ascletis Pharma Advances Acne Treatment with Pre-NDA Completion
4M ago
1672
Ascletis Pharma Advances ASC35 for Obesity Treatment
PremiumCompany Announcements
Ascletis Pharma Advances ASC35 for Obesity Treatment
4M ago
1672
Ascletis Pharma Announces Share Repurchase Plan to Enhance Shareholder Value
PremiumCompany Announcements
Ascletis Pharma Announces Share Repurchase Plan to Enhance Shareholder Value
4M ago
1672
Ascletis Pharma Grants 650,000 Share Options to Employees
PremiumCompany Announcements
Ascletis Pharma Grants 650,000 Share Options to Employees
4M ago
1672
Ascletis Pharma’s ASC47 Shows Promising Results in Obesity Treatment
PremiumCompany Announcements
Ascletis Pharma’s ASC47 Shows Promising Results in Obesity Treatment
4M ago
1672
Ascletis Pharma Reports Successful Phase III Trial Results for Acne Treatment
PremiumCompany AnnouncementsAscletis Pharma Reports Successful Phase III Trial Results for Acne Treatment
5M ago
1672
Ascletis Pharma Reports Promising Phase Ib Results for Obesity Treatment
Premium
Company Announcements
Ascletis Pharma Reports Promising Phase Ib Results for Obesity Treatment
5M ago
1672
Ascletis Pharma’s Controlling Shareholders Commit to Share Lock-Up Amid Clinical Trials
Premium
Company Announcements
Ascletis Pharma’s Controlling Shareholders Commit to Share Lock-Up Amid Clinical Trials
5M ago
1672

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >